BOSTON--(BUSINESS WIRE)--Feb. 14, 2006--Point Therapeutics, Inc. (NASDAQ: POTP) announced today a collaboration with the National Cancer Institute (NCI) to evaluate Point’s oral anti-tumor drug candidate, talabostat, in combination with chemotherapy in pediatric patients with solid tumors. The primary objectives of the Phase 1 study are to evaluate the safety and dosing of talabostat in combination with chemotherapy in the pediatric population.
